Study to Assess Safety & Tolerability of AZD2281 in Combination With Bevacizumab in Patients With Advanced Solid Tumours

Inclusion Criteria: * Histologically confirmed metastatic cancer, not amenable to surgery or radiation therapy with curative intent * Adequate bone marrow, kidney and liver function in accordance with laboratory parameters set out in the protocol * Estimated life expectancy of at least 12 weeks Exclusion Criteria: * Disorders that may put the patient at risk of bleeding, including gastrointestinal perforation, intra-abdominal abcess, major surgery of the chest or abdomen, previous haemorrhage, coughing up blood or thrombotic event * Hypertension (high blood pressure) or significant cardiovascular disease * Hypersensitivity to Chinese hamster ovary cell products or other recombinant or humanised antibodies